New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.» Read More
LONDON, Feb 12- Reckitt Benckiser Group said on Wednesday the strategic review of its pharmaceuticals business was ongoing and that it would update investors over the course of the year. The company said in October it was considering all options for the business, which could include selling it, spinning it off, or keeping it.
Some of Friday's midday movers:
Feb 7- Merck& Co said on Friday it will pay $100 million to resolve all U.S. product liability lawsuits alleging it downplayed serious health risks involving its NuvaRing intrauterine contraceptive device.
Feb 7- Merck& Co said on Friday it has agreed to pay $100 million to resolve all U.S. product liability lawsuits involving its NuvaRing contraceptive product.
Feb 6- Merck& Co has agreed to pay $100 million to settle hundreds of lawsuits accusing the U.S. drugmaker of downplaying serious health risks associated with its NuvaRing contraceptive device, Bloomberg reported on Thursday, citing people familiar with the deal.
*Q4 sales $6.84 bln vs consensus $6.88 bln. *Q4 core earnings per share $1.23 vs consensus $1.16. LONDON, Feb 6- AstraZeneca expects earnings to keep falling in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from late May.
*Q4 core earnings per share $1.23 vs $1.16. LONDON, Feb 6- AstraZeneca expects earnings to continue to fall in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from May. Shares in AstraZeneca fell 1 percent in early trading.
For example, the price discussed for 24 weeks of Sovaldi therapy would run about $2,500 for certain patients at public hospitals, community clinics and non-governmental agencies in India, the Hindu Business Line reported earlier this week.
Stocks fell on Wednesday after data had companies adding fewer employees to their payrolls than anticipated.
U.S. bonds edged lower on Wednesday, with yields rising after private payroll data missed market expectations.
U.S. stock index futures signaled a lower open on Wednesday, as Wall Street considered the ADP employment report.
Feb 5- Merck& Co Inc's quarterly profit and sales just missed expectations as its medicines faced competition from cheaper generics, but shares rose 1.5 percent on enthusiasm for newly announced cancer-drug partnerships with rival U.S. companies.
Merck reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines.
GSK said sales rose five percent in the fourth quarter of last year, narrowly beating expectations and indicating that the U.K. pharmaceutical giant's fortunes may be picking up.
Some of the names on the move ahead of the open.
Feb 5- Merck& Co Inc reported quarterly sales that were slightly lower than expected, hurt by competition from cheaper generic medicines, and predicted full-year earnings at the lower end of analysts' expectations. The second-biggest U.S. drugmaker said on Wednesday it earned $781 million, or 26 cents per share, in the fourth quarter.
Feb 5- Merck& Co Inc reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines. The second-biggest U.S. drugmaker said on Wednesday it earned $781 million, or 26 cents per share, in the fourth quarter. Wall Street was expecting $11.36 billion, according to Thomson Reuters I/B/E/S.
ADP's private sector jobs report and data on services sector activity could set the direction for stocks Wednesday.
*Ablynx initially to get 20 mln euros, plus 10.7 mln for research. *Ablynx shares gain up to 6.9 pct. BRUSSELS, Feb 3- Belgian biotech company Ablynx has signed a deal with Merck& Co worth up to 1.7 billion euros to develop ways of triggering the body to fight cancer by itself.
Traders await Friday's jobs report and watch emerging markets to see if the selloff can be contained.